How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation
Journal of Thrombosis and Haemostasis · 2025-06 · 23 (6) · 2060-2066
DOI: 10.1016/j.jtha.2025.02.026 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-06. Verfasst von Nicolas Gendron und 4 weiteren Autor:innen. Beteiligte Einrichtung: Paris Cité University, INSERM, Paris Cardiovascular Research Centre, Team Endotheliopathy and Hemostasis disorders, Paris, France; Hematology Departm…. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Blood Coagulation, Heparin, Anticoagulants. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: International Society on Thrombosis and Haemostasis.
Abstract (Originalsprache)
Monitoring unfractionated heparin (UFH) to ensure effective anticoagulation may be performed using anti-factor Xa activity (anti-Xa) instead of the activated partial thromboplastin time. However, in patients who have been treated with oral factor (F)Xa inhibitors (apixaban, rivaroxaban, and edoxaban) while switching to UFH therapy, there is a risk that these oral anti-FXa drugs could interfere with UFH-calibrated anti-Xa monitoring. This may lead to inappropriate anticoagulation management. This report of the International Society on Thrombosis and Haemostasis (ISTH) Subcommittee on Control of Anticoagulation summarizes the evidence on the risk of interference from previous treatment with oral FXa inhibitors and UFH anti-Xa after heparin initiation. This communication provides pragmatic recommendations for UFH initiation and management with anti-Xa monitoring after switching from oral FXa inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paris Cité University, INSERM, Paris Cardiovascular Research Centre, Team Endotheliopathy and Hemostasis disorders, Paris, France; Hematology Department, Hôpital européen Georges Pompidou, Assistance Publique Hôpitaux d…
- Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Hemostasis and Thrombosis Center, University of California, Davis Health System, Sacramento, California, USA.
- Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ontario, Canada.
- MAHSC, University of Manchester, Oxford Road, Manchester, United Kingdom.
Förderung
- International Society on Thrombosis and Haemostasis
Zitieren
APA
Gendron, N., Cuker, A., Gosselin, R. C., Castellucci, L. A., & Thachil, J. (2025). How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 23(6), 2060-2066. https://doi.org/10.1016/j.jtha.2025.02.026
Vancouver
Gendron N, Cuker A, Gosselin RC, Castellucci LA, Thachil J. How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis. 2025;23(6):2060-2066. doi:10.1016/j.jtha.2025.02.026
BibTeX
@article{Gendron2025,
author = {Gendron, Nicolas and Cuker, Adam and Gosselin, Robert C and Castellucci, Lana A and Thachil, Jecko},
title = {How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {6},
pages = {2060--2066},
doi = {10.1016/j.jtha.2025.02.026}
}
EUVIMED